Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013

Guerrero-Zotano, Ángel Gil-Gil, Miguel Williams, Amy Ruiz-Borrego, Manuel Ritzén, Hanna Ciruelos, Eva María Muñoz, Montserrat Bermejo, Begoña Margelí, Mireia Antón, Antonio Kahan, Zsuzsanna Csöszi, Tibor Alonso Murillo, Laura Murillo, Serafín Morales Lang, Istvan Rendo, Cristina Reboredo Alba, Emilio Álvarez, Pablo de la Haba-Rodriguez, Juan Álvarez, Isabel García, Andrés Herranz, Jesús Caballero, Rosalía Fisker, Helle Portela, Marta Rojo, Federico Martín, Miguel Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial

Eur. j. cancer

10.1016/j.ejca.2026.116817 2026

2026